781-463-0002
Shop by Category
Shop by Brand
Shop by Brand
Bioconjugate Drug Development
CellMosaic offers a complete drug discovery and development program for drug conjugates and drug modifications using classical linkers and polymers. Over the years, CellMosaic has delivered many high-quality conjugate drugs for customers based on our advanced conjugation processes. These processes can be modified for new conjugate drug development for our customers.
The services we provide include:
- Custom design and development of conjugation strategies to fit your needs (customer owns the rights for the compound)
- Proof-of-concept Studies: CellMosaic has in-house conjugation processes ready to quickly synthesize any drug conjugates for initial proof-of-concept studies.
- Conjugate Drug Discovery:
- Evaluation of the labeling sites
- Evaluation of the linkage or labeling chemistry (stable vs. cleavable)
- Evaluation of the linkers or polymers
- Conjugate Drug Development:
- Stability studies
- Development of purification method for drug bioconjugates
- Development of bio-analytical methods (HIC, SEC, cation or anion exchange HPLC, MS)
- pK studies of conjugate drugs in blood and tissue extracts
- Lipid formulation studies
- Process development
- Process transfer
Examples of Classical Drug Conjugates and Drug Modifications frequently done at CellMosaic:
- Peptide–small molecule drug conjugate
- Oligo-peptide conjugate
- Protein-antibody conjugate
- Protein-small molecule drug conjugate
- Polymer-small molecule drug conjugates
- Other drug conjugates such as:
- Lipidation of antibody and antibody fragments
- Pegylation of protein/peptide
- Modification of small molecule drugs such as sugar-curcumin conjugate, synthesize activated toxin
- Other bivalent conjugates such as peptide-protein, Fab-protein, Fab-oligo, BSA-toxin
- Other drug conjugates involving three or more types of molecules such as protein-antibody-dye conjugates for assay development.
Depending on the needs of a customer’s project, the typical turn-around time for synthesizing any drug conjugates for initial proof-of-concept is 6-8 weeks. Please contact us to discuss your project.
AqueaTether™ Therapeutics, a separate division of CellMosaic, has developed novel super-hydrophilic and high-loading AqueaTether™ linkers and polymers for drug conjugation. To explore this opportunity and learn more about AqueaTether™ platform technologies, please visit our website at aqttherapeutics.com.